HXNetCJC-1295
HXNet's CJC-1295 looks low-concern on purity-focused evidence: identity passed and purity stayed 99.6-99.9%. The main caveats are batch-ID gaps and quantity spread, including one +28% overfill.
Corporate records anchor HXNet to Hebei Xunou while the old domain is dead and sales have shifted into forum/Pastebin lanes. The report follows the HXTNT/KIRA/KARA reseller split, Janoshik chain-of-custody gaps, and documented refund/contamination disputes.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including HXNet rows.
Cancel anytime
| Date | Result | Test | Lab | Purity | Dosage | Label | COA |
|---|---|---|---|---|---|---|---|
| 18 Feb 2026 | Pass | dpxpaab Tested | lab name | View COA | |||
| 15 Feb 2026 | Pass | ddx7ubq Tested | lab name | View COA | |||
| 9 Feb 2026 | Pass | mrnkaa7 Tested | lab name | View COA | |||
| 15 Jan 2026 | Pass | v2jzw88 Tested | lab name | View COA | |||
About HXNet test results from Finnrick
HXNet is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 10 peptides and 162 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible HXNet peptides in this dataset are Tirzepatide (51 tests), Semaglutide (5 tests) and BPC-157 (9 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 162 recent tests.